B. Riley Says Alzheimer's Data From This Firm Has Renewed 'Investor Confidence'
- B. Riley says yesterday's readout from a pre-planned 12-month treatment interim analysis of Cassava Sciences Inc's (NASDAQ: SAVA) simufilam trial data "reinvigorate" investor confidence.
- The Company announced a pre-planned interim analysis of an ongoing open-label study of simufilam in mild-to-moderate Alzheimer's disease.
- Related Content: Cassava Sciences' Simufilam Data Shows Improved Cognition In Alzheimer's Disease.
- Analyst Mayank Mamtani has reiterated a Buy rating with a $108 price target.
- Mamtani tells investors in a research note that this cognition data update and evaluation methodology "to some extent, helps assuage investor concerns" emanating from the recent Citizen's Petition.
- Related: Cassava Sciences Shares Sink With Alzheimer's Drug Mired In Controversy.
- But the analyst still asserts that the Company needs supportive 12-month biomarker analyses.
- Price Action: SAVA stock is up 16.20% at $60.71 during the market session on the last check Thursday.
Latest Ratings for SAVA
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jan 2022 | B. Riley Securities | Maintains | Buy | |
| Jul 2021 | HC Wainwright & Co. | Maintains | Buy | |
| Jun 2021 | B. Riley Securities | Maintains | Buy |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Biotech Long Ideas News Health Care Reiteration Analyst Ratings Movers Trading Ideas
